212 related articles for article (PubMed ID: 38444199)
1. Comparison of the oncolytic activity of a replication-competent and a replication-deficient herpes simplex virus 1.
Lindner G; Walter A; Magnus CL; Rosenhammer K; Holoborodko B; Koch V; Hirsch S; Grossmann L; Li S; Knipe DM; DeLuca N; Schuler-Thurner B; Gross S; Schwertner B; Toelge M; Rohrhofer A; Stöckl S; Bauer RJ; Knoll G; Ehrenschwender M; Haferkamp S; Schmidt B; Schuster P
Immunology; 2024 Jun; 172(2):279-294. PubMed ID: 38444199
[TBL] [Abstract][Full Text] [Related]
2. The Oncolytic Herpes Simplex Virus Talimogene Laherparepvec Shows Promising Efficacy in Neuroendocrine Cancer Cell Lines.
Kloker LD; Berchtold S; Smirnow I; Schaller M; Fehrenbacher B; Krieg A; Sipos B; Lauer UM
Neuroendocrinology; 2019; 109(4):346-361. PubMed ID: 31280274
[TBL] [Abstract][Full Text] [Related]
3. Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1.
Thomas S; Kuncheria L; Roulstone V; Kyula JN; Mansfield D; Bommareddy PK; Smith H; Kaufman HL; Harrington KJ; Coffin RS
J Immunother Cancer; 2019 Aug; 7(1):214. PubMed ID: 31399043
[TBL] [Abstract][Full Text] [Related]
4. Generation of an Oncolytic Herpes Simplex Virus 1 Expressing Human MelanA.
Boscheinen JB; Thomann S; Knipe DM; DeLuca N; Schuler-Thurner B; Gross S; Dörrie J; Schaft N; Bach C; Rohrhofer A; Werner-Klein M; Schmidt B; Schuster P
Front Immunol; 2019; 10():2. PubMed ID: 30723467
[TBL] [Abstract][Full Text] [Related]
5. Molecular Pathways: Mechanism of Action for Talimogene Laherparepvec, a New Oncolytic Virus Immunotherapy.
Kohlhapp FJ; Kaufman HL
Clin Cancer Res; 2016 Mar; 22(5):1048-54. PubMed ID: 26719429
[TBL] [Abstract][Full Text] [Related]
6. Talimogene Laherparepvec (T-VEC) and Other Oncolytic Viruses for the Treatment of Melanoma.
Bommareddy PK; Patel A; Hossain S; Kaufman HL
Am J Clin Dermatol; 2017 Feb; 18(1):1-15. PubMed ID: 27988837
[TBL] [Abstract][Full Text] [Related]
7. Intratumoral Immunotherapy-Update 2019.
Hamid O; Ismail R; Puzanov I
Oncologist; 2020 Mar; 25(3):e423-e438. PubMed ID: 32162802
[TBL] [Abstract][Full Text] [Related]
8. Novel Oncolytic Herpes Simplex Virus 1 VC2 Promotes Long-Lasting, Systemic Anti-melanoma Tumor Immune Responses and Increased Survival in an Immunocompetent B16F10-Derived Mouse Melanoma Model.
Uche IK; Fowlkes N; Vu L; Watanabe T; Carossino M; Nabi R; Del Piero F; Rudd JS; Kousoulas KG; Rider PJF
J Virol; 2021 Jan; 95(3):. PubMed ID: 33177208
[TBL] [Abstract][Full Text] [Related]
9. Talimogene laherparepvec (T-VEC) as cancer immunotherapy.
Kohlhapp FJ; Zloza A; Kaufman HL
Drugs Today (Barc); 2015 Sep; 51(9):549-58. PubMed ID: 26488034
[TBL] [Abstract][Full Text] [Related]
10. Talimogene laherparepvec (T-Vec) for the treatment of melanoma and other cancers.
Grigg C; Blake Z; Gartrell R; Sacher A; Taback B; Saenger Y
Semin Oncol; 2016 Dec; 43(6):638-646. PubMed ID: 28061981
[TBL] [Abstract][Full Text] [Related]
11. MEK inhibition enhances oncolytic virus immunotherapy through increased tumor cell killing and T cell activation.
Bommareddy PK; Aspromonte S; Zloza A; Rabkin SD; Kaufman HL
Sci Transl Med; 2018 Dec; 10(471):. PubMed ID: 30541787
[TBL] [Abstract][Full Text] [Related]
12. Combined cytotoxic activity of an infectious, but non-replicative herpes simplex virus type 1 and plasmacytoid dendritic cells against tumour cells.
Thomann S; Boscheinen JB; Vogel K; Knipe DM; DeLuca N; Gross S; Schuler-Thurner B; Schuster P; Schmidt B
Immunology; 2015 Oct; 146(2):327-38. PubMed ID: 26194553
[TBL] [Abstract][Full Text] [Related]
13. Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1-derived oncolytic immunotherapy.
Harrington KJ; Puzanov I; Hecht JR; Hodi FS; Szabo Z; Murugappan S; Kaufman HL
Expert Rev Anticancer Ther; 2015; 15(12):1389-403. PubMed ID: 26558498
[TBL] [Abstract][Full Text] [Related]
14. [The Advances of Oncolytic Herpes Simplex Virus in Cancer Therapy].
Hao M; Huang C; Xia N
Bing Du Xue Bao; 2016 Jul; 32(4):516-22. PubMed ID: 29996042
[TBL] [Abstract][Full Text] [Related]
15. Talimogene laherparepvec (T-VEC) for the treatment of advanced melanoma.
Johnson DB; Puzanov I; Kelley MC
Immunotherapy; 2015; 7(6):611-9. PubMed ID: 26098919
[TBL] [Abstract][Full Text] [Related]
16. Biodistribution, shedding, and transmissibility of the oncolytic virus talimogene laherparepvec in patients with melanoma.
Andtbacka RHI; Amatruda T; Nemunaitis J; Zager JS; Walker J; Chesney JA; Liu K; Hsu CP; Pickett CA; Mehnert JM
EBioMedicine; 2019 Sep; 47():89-97. PubMed ID: 31409575
[TBL] [Abstract][Full Text] [Related]
17. Oncolytic Virotherapy by HSV.
Watanabe D; Goshima F
Adv Exp Med Biol; 2018; 1045():63-84. PubMed ID: 29896663
[TBL] [Abstract][Full Text] [Related]
18. Enhancing the HSV-1-mediated antitumor immune response by suppressing Bach1.
Pan C; Cai Q; Li X; Li L; Yang L; Chen Y; Liu J; Liu W; Gao M; Sui T; Wang X; Fan H; Ruan J; Shi Y; Chen S; Cheng LS; Liu J; Yang H; Cheng G
Cell Mol Immunol; 2022 Apr; 19(4):516-526. PubMed ID: 34983952
[TBL] [Abstract][Full Text] [Related]
19. Talimogene Laherparepvec: An Oncolytic Virus Therapy for Melanoma.
Corrigan PA; Beaulieu C; Patel RB; Lowe DK
Ann Pharmacother; 2017 Aug; 51(8):675-681. PubMed ID: 28351167
[TBL] [Abstract][Full Text] [Related]
20. High response rates for T-VEC in early metastatic melanoma (stage IIIB/C-IVM1a).
Franke V; Berger DMS; Klop WMC; van der Hiel B; van de Wiel BA; Ter Meulen S; Wouters MWJM; van Houdt WJ; van Akkooi ACJ
Int J Cancer; 2019 Aug; 145(4):974-978. PubMed ID: 30694555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]